The hypouricemic effect of Balanophora laxiflora extracts and derived phytochemicals in hyperuricemic mice

Shang Tse Ho, Yu Tang Tung, Chi Chang Huang, Chao Lin Kuo, Chi Chen Lin, Suh Ching Yang, Jyh Horng Wu

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The objective of this study is to evaluate the lowering of uric acid using Balanophora laxiflora extracts and derived phytochemicals on potassium-oxonate-(PO-) induced hyperuricemia in mice. The results revealed that ethyl acetate (EtOAc) fraction of B. laxiflora extracts exhibited strong xanthine-oxidase-(XOD-) inhibitory activity. In addition, among the 10 subfractions (EA110) derived from EtOAc fraction, subfraction 8 (EA8) exhibited the best XOD-inhibitory activity. Four specific phytochemicals, 1-O-(E)-caffeoyl - D-glucopyranose (1), 1-O-(E)-p-coumaroyl - D-glucopyranose (2), 1,3-di-O-galloyl-4,6-(S)-hexahydroxydiphenoylβ- D-glucopyranose (3), and 1-O-(E)-caffeoyl-4,6-(S)-hexahydroxydiphenoyl - D-glucopyranose (4), were further isolated and identified from this subfraction. Compounds 3 and 4 exhibited the strongest XOD-inhibitory activity compared with other compounds, and both hydrolyzable tannins were determined to be noncompetitive inhibitors according to the Lineweaver-Burk plot. On the other hand, the in vivo hypouricemic effect in hyperuricemic mice was consistent with XOD-inhibitory activity, indicating that B. laxiflora extracts and derived phytochemicals could be potential candidates as new hypouricemic agents.

Original languageEnglish
Article number910152
JournalEvidence-based Complementary and Alternative Medicine
Volume2012
DOIs
Publication statusPublished - 2012

Fingerprint

Phytochemicals
Hydrolyzable Tannins
Hyperuricemia
Xanthine Oxidase
Uric Acid

ASJC Scopus subject areas

  • Complementary and alternative medicine

Cite this

The hypouricemic effect of Balanophora laxiflora extracts and derived phytochemicals in hyperuricemic mice. / Ho, Shang Tse; Tung, Yu Tang; Huang, Chi Chang; Kuo, Chao Lin; Lin, Chi Chen; Yang, Suh Ching; Wu, Jyh Horng.

In: Evidence-based Complementary and Alternative Medicine, Vol. 2012, 910152, 2012.

Research output: Contribution to journalArticle

@article{e47d8753c30846e49e6451471f4eb19e,
title = "The hypouricemic effect of Balanophora laxiflora extracts and derived phytochemicals in hyperuricemic mice",
abstract = "The objective of this study is to evaluate the lowering of uric acid using Balanophora laxiflora extracts and derived phytochemicals on potassium-oxonate-(PO-) induced hyperuricemia in mice. The results revealed that ethyl acetate (EtOAc) fraction of B. laxiflora extracts exhibited strong xanthine-oxidase-(XOD-) inhibitory activity. In addition, among the 10 subfractions (EA110) derived from EtOAc fraction, subfraction 8 (EA8) exhibited the best XOD-inhibitory activity. Four specific phytochemicals, 1-O-(E)-caffeoyl - D-glucopyranose (1), 1-O-(E)-p-coumaroyl - D-glucopyranose (2), 1,3-di-O-galloyl-4,6-(S)-hexahydroxydiphenoylβ- D-glucopyranose (3), and 1-O-(E)-caffeoyl-4,6-(S)-hexahydroxydiphenoyl - D-glucopyranose (4), were further isolated and identified from this subfraction. Compounds 3 and 4 exhibited the strongest XOD-inhibitory activity compared with other compounds, and both hydrolyzable tannins were determined to be noncompetitive inhibitors according to the Lineweaver-Burk plot. On the other hand, the in vivo hypouricemic effect in hyperuricemic mice was consistent with XOD-inhibitory activity, indicating that B. laxiflora extracts and derived phytochemicals could be potential candidates as new hypouricemic agents.",
author = "Ho, {Shang Tse} and Tung, {Yu Tang} and Huang, {Chi Chang} and Kuo, {Chao Lin} and Lin, {Chi Chen} and Yang, {Suh Ching} and Wu, {Jyh Horng}",
year = "2012",
doi = "10.1155/2012/910152",
language = "English",
volume = "2012",
journal = "Evidence-based Complementary and Alternative Medicine",
issn = "1741-427X",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - The hypouricemic effect of Balanophora laxiflora extracts and derived phytochemicals in hyperuricemic mice

AU - Ho, Shang Tse

AU - Tung, Yu Tang

AU - Huang, Chi Chang

AU - Kuo, Chao Lin

AU - Lin, Chi Chen

AU - Yang, Suh Ching

AU - Wu, Jyh Horng

PY - 2012

Y1 - 2012

N2 - The objective of this study is to evaluate the lowering of uric acid using Balanophora laxiflora extracts and derived phytochemicals on potassium-oxonate-(PO-) induced hyperuricemia in mice. The results revealed that ethyl acetate (EtOAc) fraction of B. laxiflora extracts exhibited strong xanthine-oxidase-(XOD-) inhibitory activity. In addition, among the 10 subfractions (EA110) derived from EtOAc fraction, subfraction 8 (EA8) exhibited the best XOD-inhibitory activity. Four specific phytochemicals, 1-O-(E)-caffeoyl - D-glucopyranose (1), 1-O-(E)-p-coumaroyl - D-glucopyranose (2), 1,3-di-O-galloyl-4,6-(S)-hexahydroxydiphenoylβ- D-glucopyranose (3), and 1-O-(E)-caffeoyl-4,6-(S)-hexahydroxydiphenoyl - D-glucopyranose (4), were further isolated and identified from this subfraction. Compounds 3 and 4 exhibited the strongest XOD-inhibitory activity compared with other compounds, and both hydrolyzable tannins were determined to be noncompetitive inhibitors according to the Lineweaver-Burk plot. On the other hand, the in vivo hypouricemic effect in hyperuricemic mice was consistent with XOD-inhibitory activity, indicating that B. laxiflora extracts and derived phytochemicals could be potential candidates as new hypouricemic agents.

AB - The objective of this study is to evaluate the lowering of uric acid using Balanophora laxiflora extracts and derived phytochemicals on potassium-oxonate-(PO-) induced hyperuricemia in mice. The results revealed that ethyl acetate (EtOAc) fraction of B. laxiflora extracts exhibited strong xanthine-oxidase-(XOD-) inhibitory activity. In addition, among the 10 subfractions (EA110) derived from EtOAc fraction, subfraction 8 (EA8) exhibited the best XOD-inhibitory activity. Four specific phytochemicals, 1-O-(E)-caffeoyl - D-glucopyranose (1), 1-O-(E)-p-coumaroyl - D-glucopyranose (2), 1,3-di-O-galloyl-4,6-(S)-hexahydroxydiphenoylβ- D-glucopyranose (3), and 1-O-(E)-caffeoyl-4,6-(S)-hexahydroxydiphenoyl - D-glucopyranose (4), were further isolated and identified from this subfraction. Compounds 3 and 4 exhibited the strongest XOD-inhibitory activity compared with other compounds, and both hydrolyzable tannins were determined to be noncompetitive inhibitors according to the Lineweaver-Burk plot. On the other hand, the in vivo hypouricemic effect in hyperuricemic mice was consistent with XOD-inhibitory activity, indicating that B. laxiflora extracts and derived phytochemicals could be potential candidates as new hypouricemic agents.

UR - http://www.scopus.com/inward/record.url?scp=84863686319&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863686319&partnerID=8YFLogxK

U2 - 10.1155/2012/910152

DO - 10.1155/2012/910152

M3 - Article

VL - 2012

JO - Evidence-based Complementary and Alternative Medicine

JF - Evidence-based Complementary and Alternative Medicine

SN - 1741-427X

M1 - 910152

ER -